The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC phase II clinical trial ( NCT07285070) in ...
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human ...
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...
Zevra plans to expand KP1077 clinical program to address multiple rare sleep disorders with trials initiating in 2023 CELEBRATION, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc.
The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1 +, a DNA plasmid vaccine, in patients with advanced melanoma, scheduled to commence ...
The FDA has accepted an investigational new drug application from a global biotechnology company for its investigational, ...
Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - ...
Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) ...
The FDA cleared an investigational new drug application to advance NOV05 in a phase 2 clinical trial in noninfectious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results